Next Article in Journal
A Role for Circular Non-Coding RNAs in the Pathogenesis of Sporadic Parathyroid Adenomas and the Impact of Gender-Specific Epigenetic Regulation
Next Article in Special Issue
The Role of Lipids in Parkinson’s Disease
Previous Article in Journal
The Fate of Fusions
Previous Article in Special Issue
Epigenetic Study in Parkinson’s Disease: A Pilot Analysis of DNA Methylation in Candidate Genes in Brain
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Cells 2019, 8(1), 14;

Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease

Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
Center for Genomic and Regenerative Medicine, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
Medical Technology Innovation Center, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan
Authors to whom correspondence should be addressed.
Received: 29 November 2018 / Revised: 20 December 2018 / Accepted: 25 December 2018 / Published: 29 December 2018
(This article belongs to the Special Issue The Molecular and Cellular Basis for Parkinson's Disease)
Full-Text   |   PDF [414 KB, uploaded 29 December 2018]   |  
  |   Review Reports


Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear. To assess metabolic status under zonisamide treatment in PD, we performed a pilot study using a comprehensive metabolome analysis. Plasma samples were collected for at least one year from 30 patients with PD: 10 without zonisamide medication and 20 with zonisamide medication. We performed comprehensive metabolome analyses of plasma with capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography time-of-flight mass spectrometry. We also measured disease severity using Hoehn and Yahr (H&Y) staging and the Unified Parkinson’s Disease Rating Scale (UPDRS) motor section, and analyzed blood chemistry. In PD with zonisamide treatment, 15 long-chain acylcarnitines (LCACs) tended to be increased, of which four (AC(12:0), AC(12:1)-1, AC(16:1), and AC(16:2)) showed statistical significance. Of these, two LCACs (AC(16:1) and AC(16:2)) were also identified by partial least squares analysis. There was no association of any LCAC with age, disease severity, levodopa daily dose, or levodopa equivalent dose. Because an upregulation of LCACs implies improvement of mitochondrial β-oxidation, zonisamide might be beneficial for mitochondrial β-oxidation, which is suppressed in PD. View Full-Text
Keywords: Parkinson’s disease; fatty acid β-oxidation; long-chain acylcarnitine Parkinson’s disease; fatty acid β-oxidation; long-chain acylcarnitine

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Ueno, S.-I.; Saiki, S.; Fujimaki, M.; Takeshige-Amano, H.; Hatano, T.; Oyama, G.; Ishikawa, K.-I.; Yamaguchi, A.; Nojiri, S.; Akamatsu, W.; Hattori, N. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease. Cells 2019, 8, 14.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top